Post-discontinuation Survival in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Pooled Analysis of Prospective Cohort Studies

Post-discontinuation Survival in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Pooled Analysis of Prospective Cohort Studies

Introduction: The safety of discontinuing immune checkpoint inhibitors (ICIs) because of a durable response in patients with advanced NSCLC remains uncertain, and post-discontinuation survival outcomes based on the reason for cessation are not well defined. Methods: A pooled analysis was conducted u...

Full description

Saved in:
Bibliographic Details
Main Authors: Yusuke Inoue, MD, PhD, Yoshihiro Kitahara, MD, Masato Karayama, MD, PhD, Kazuhiro Asada, MD, PhD, Koji Nishimoto, MD, PhD, Shun Matsuura, MD, PhD, Dai Hashimoto, MD, PhD, Masato Fujii, MD, PhD, Takashi Matsui, MD, PhD, Nao Inami, MD, Mikio Toyoshima, MD, PhD, Hiroyuki Matsuda, MD, PhD, Masaki Ikeda, MD, PhD, Mitsuru Niwa, MD, PhD, Yusuke Kaida, MD, PhD, Masaki Sato, MD, PhD, Yasuhiro Ito, MD, Hideki Yasui, MD, PhD, Yuzo Suzuki, MD, PhD, Hironao Hozumi, MD, PhD, Kazuki Furuhashi, MD, PhD, Noriyuki Enomoto, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Naoki Inui, MD, PhD, Takafumi Suda, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:JTO Clinical and Research Reports
Subjects:
Immune checkpoint inhibitors
non-small cell lung cancer
discontinuation
post-discontinuation survival
immune-related adverse event
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000645
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364325000645

Similar Items